机构:[1]Department of Hepato-Biliary Surgery, Dongguan People’s Hospital, Southern Medical University, Dongguan 523000, China[2]Department of Traditional Chinese Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China中山大学附属第二医院[3]Department of Gastroenterology, Dongguan People’s Hospital, Southern Medical University, Dongguan 523000, China[4]Department of Oncology, Dongguan People’s Hospital, Southern Medical University, Dongguan 523000, China[5]Department of Hepato-Biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China中山大学附属第二医院[6]Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China中山大学附属第二医院
The authors received funding from Provincial Basic and Applied
Basic Research Project (Provincial Natural Fund) Doctor startup
project (2016A030310089).
第一作者机构:[1]Department of Hepato-Biliary Surgery, Dongguan People’s Hospital, Southern Medical University, Dongguan 523000, China
通讯作者:
通讯机构:[1]Department of Hepato-Biliary Surgery, Dongguan People’s Hospital, Southern Medical University, Dongguan 523000, China[*1]Department of Hepato-Biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
推荐引用方式(GB/T 7714):
Hanqin Weng,Lexiang Zeng,Linhui Cao,et al.circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324.[J].MOLECULAR THERAPY-NUCLEIC ACIDS.2021,23:811-820.doi:10.1016/j.omtn.2020.12.019.
APA:
Hanqin Weng,Lexiang Zeng,Linhui Cao,Tao Chen,Yanshan Li...&Yibiao Ye.(2021).circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324..MOLECULAR THERAPY-NUCLEIC ACIDS,23,
MLA:
Hanqin Weng,et al."circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324.".MOLECULAR THERAPY-NUCLEIC ACIDS 23.(2021):811-820